We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byRoberta Booker
Modified about 1 year ago
GeneGo. Your GPS in pathway analysis. Confidential © GeneGo Inc. Parkinson’s Disease GWAS and enrichment with MetaCore™ Ewan Hunter, PhD January 18, 2010
Confidential © GeneGo Inc.2 GeneGo Services Knowledge base Management Pathway Analysis Platforms Develop Ontologies Develop Disease platforms Annotation and Curation Data Repository Project analysis (on/off site) Wet Lab Services Data parsers Maps, interactions, interface skins Customization/ Integration Compound Assessment analysis
Confidential © GeneGo Inc.3 MetaMiner Initiatives Eli Lilly Astra Zeneca Chicago Children’s Hospital University of Glasgow Sheffield Queensland USC Research and DiscoveryClinical CNS Oncology Skin Stem Cells TSRI Cardiac Jackie Immunology Metabolic Knowledge Management Information Technology Vertex IOP Pharma TBA Eli Lilly Tgen Van Andel Harvard Johns Hopkins Exclusive PC contract with top Pharma GSK Top Pharma Nutrition TBA ToxicologyDrug Metabolism/ Positioning Dry Eye Exclusive Project 3 cosmetic co’s FDA ISB University of Amsterdam Respiratory TSRI Infectious Disease TBA Cystic Fibrosis Complete
Confidential © GeneGo Inc.4 MetaBase Content Overview Database Human genes45.471 Human SwissProt proteins20.328 Mouse genes61.311 Mouse SwissProt proteins16.209 Rat genes36.870 Rat SwissProt proteins7.459 Chemical compounds691.896 Compounds with structures673.207 Drugs5.594 - FDA approved drugs1.085 - EU approved drugs169 - Drugs approved by other committees692 - US withdrawn drugs140 - EU withdrawn drugs54 - Clinical trial drugs2.258 - Discontinued drugs1.205 - Preclinical drugs134 - Biologics618 Endogenous compounds4.776 Nutritional compounds93 Metabolite of xenobiotic8.199 Networkable Objects Human genes in network19.910 Mouse genes in network18.381 Rat genes in network16.228 Chemical compounds221.076 Drugs2.737 Endogenous compounds2.449 Metabolic Reactions8.899 Pubmed journals2.664 Pubmed articles (total)758.139 Pubmed articles (single citation)130.058 Total amount of interactions941.946 Protein-Protein365.129 Compound – Protein502.572 Compound – Compound 9.618 Protein -Reaction19.449 Substrate, Product-Reaction29.366 RNA – Protein15.812
Confidential © GeneGo Inc.5 GeneGo Ontologies Ontologies with graphic content GeneGo maps: 808 (regulatory processes maps Disease maps Metabolic maps) GeneGo networks 942 UNIQUE for GeneGo (regulatory networks drug target networks toxicity networks metabolic networks disease biomarker networks) Groups and Complexes: 2247 UNIQUE for GeneGo Schemas for human, mouse or rat ACM2 and ACM4 activation of ERK Inflammation_IL-6 signaling NF-kB_HUMAN
Confidential © GeneGo Inc.6 GeneGo Pathway Formats GeneGo Canonical MapsGeneGo Networks Insulin Receptor Signaling PathwaySignal transduction_Insulin signaling Total number to date: 808 Subset of a bigger-global network Static, pre-built Interactive Multistep Well accepted in the field “Review-article” style- mainstream signaling Total number to date: 942 Dynamic Interactive Pre-built and build your own Bigger-global network Include single or multistep Include newer findings, more than mainstream signaling
Confidential © GeneGo Inc.7 How to Approach MetaCore Input list Data Mining Functional Representation What do the items on the list collectively represent? Connectivity How do the items on the list connect?
Confidential © GeneGo Inc.8 GWAS- Pakinson’s Disease Data: SNP identifiers, allelic frequency and odds ratio The odds ratio = as the ratio of the odds of an event occurring in one group (PD siblings) to the odds of it occurring in another group (non-PD siblings). odds ratio =1 condition or event under study is equally likely in both groups. odds ratio > 1 condition or event is more likely in the first group odds ratio <1 condition or event is less likely in the second group.
Confidential © GeneGo Inc.9 Data Format and Data Loading
Confidential © GeneGo Inc.10 Define Thresholds
Confidential © GeneGo Inc.11 Single Experiment Workflow: Enrichment Histograms for Canonical Pathway Maps
Confidential © GeneGo Inc.12 Alzheimer's disease: extracellular Amyloid beta toxicity.
Confidential © GeneGo Inc.13 Disease Biomarker Map Overlay
Confidential © GeneGo Inc.14 Alzheimer's disease: extracellular Amyloid beta toxicity Ca++ Channels
Confidential © GeneGo Inc.15 From this table we can also appreciate that another gene of interest from this canonical pathway map is not only the Amyloid beta A4 precursor protein but that 3 subunits of the Ca2 channel have a significant association to Parkinson’s. This is of interest as there are studies that suggest the disruption in Ca2+ homeostasis within the dopamine neurons of the substantia nigra lead to loss of these SN neurons Sulzer and Schmitz (2007) Parkinson’s Disease: Return of an Old Prime Suspect. Neuron, 55, 8-10 Interesting SNPs and Associated Genes for Parkinson’s
Confidential © GeneGo Inc.16 A recent review in Trends in Neurosciences, “Calcium homeostasis, selective vulnerability and Parkinson's disease” ( TINS, 23 March 2009 doi:10.1016/) Has pointed that a very good theory of neuronal degeration/death of the dopamine neurons in the substantia nigra pas compacta (SNc) Is to do with the homeostatic control of Ca2+ within these neurons. The neurons of the SNc are selectively vulnerable to homeostatic Ca2+ stress as particularly Ca2+ ion channels are responsible for maintaining an autonomous pacemaking within these neurons. This Function is unlike other adult neurons in the brain, the pacemaking activity is believed to be important in maintaining dopamine levels in regions that are innervated by these neurons, particularly the striatum. The L-type Ca2+ channels are responsible for this pacemaker activity within the SNc neurons and the combined GWAS and Enrichment analysis within MetaCore, we have indentified 3 subunits of the Ca2+ channel Recent Review in the Parkinson’s Disease Field
Confidential © GeneGo Inc.17 A recent review in Trends in Neurosciences, “Calcium homeostasis, selective vulnerability and Parkinson's disease” ( TINS, 23 March 2009 doi:10.1016/) Has pointed that a very good theory of neuronal degeration/death of the dopamine neurons in the substantia nigra pas compacta (SNc) Is to do with the homeostatic control of Ca2+ within these neurons. The neurons of the SNc are selectively vulnerable to homeostatic Ca2+ stress as particularly Ca2+ ion channels are responsible for maintaining an autonomous pacemaking within these neurons. This Function is unlike other adult neurons in the brain, the pacemaking activity is believed to be important in maintaining dopamine levels in regions that are innervated by these neurons, particularly the striatum. The L-type Ca2+ channels are responsible for this pacemaker activity within the SNc neurons and the combined GWAS and Enrichment analysis within MetaCore, we have indentified 3 subunits of the Ca2+ channel Recent Review in the Parkinson’s Disease Field
Confidential © GeneGo Inc.18 The L-type Ca2+ channels are responsible for this pacemaker activity within the SNc neurons and the combined GWAS and Enrichment analysis within MetaCore, we indentified 3 subunits of the Ca2+ channel The beta-subunit of the L-type Ca2+ has a large Odds Ratio (1.781) And relatively significant association p-value 0.0094 for association To Parkinson’s Disease Recent findings in relation to results found with MetaCore™
Confidential © GeneGo Inc.19 Therefore Is PD simply a reflection of accelerated aging in neurons that rely too heavily upon Ca2+ channels to do theirbusiness? Age is undoubtedly the single strongest risk factor for PD. The ‘wear and tear’ theory of PD does not require a pathogenic agent. Moreover, it argues that there is no disease ‘onset’ other than the one created by the emergence of symptoms when the surviving SNc DA neurons Are incapable of fully compensating for the loss of neighboring neurons (1). It also predicts that we will all develop symptoms if we live long enough. Why then do some people become symptomatic in their 50 s, others in their 60 s or 70 s or not at all? Genetic and environmental factors certainly could account for this variation One of these genetic factors could be mutations within the Ca2+ L-type channel, which through malfunction, the Homeostasis of Ca2+ is not regulated and accelerate the ageing process within these neurons. (1) Zigmond, M.J. et al. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290–296 Conclusion of GWAS and MetaCore
Confidential © GeneGo Inc.20 Can PD be prevented? If PD is a consequence of Ca2+-accelerated aging in SNc DA neurons (and in those neurons with a similar phenotype) then reducing Ca2+ flux should delay the onset of PD symptoms and slow its progression. A recent case-control study of hypertensive patients found a significant reduction in the observed risk of PD with Calcium channel Antagonists( CCA) use, but not with medications that reduce blood pressure in other ways
Copyright GeneGo Cover Slide Cytoscape Reteat November 7 th 2007 Mark Hughes PhD.
The Application of the Scientific Method: Preclinical Trials Copyright PEER.tamu.edu.
Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
Complex Adaptive Systems and Human Health: Statistical Approaches in Pharmacogenomics Kim E. Zerba, Ph.D. Bristol-Myers Squibb FDA/Industry Statistics.
Systematic Analysis of Interactome: A New Trend in Bioinformatics KOCSEA Technical Symposium 2010 Young-Rae Cho, Ph.D. Assistant Professor Department of.
Genetic Screening for Alzheimer’s Disease Thorstensen: Genetic Screening for Alzheimer's Disease 1.
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
PDbase : A database of Parkinson’s Disease-related genes and genetic variation using substantia nigra ESTs Jin Ok Yang Korean BioInformation Center (KOBIC)
An atlas of genetic influences on human blood metabolites Nature Genetics 2014 Jun;46(6)
Manolis Kellis Broad Institute of MIT and Harvard
Genetic Variation Influences Glutamate Concentrations in Brains of Patients with Multiple Sclerosis Robby Bonanno.
Stratifying RTT Patients for Clinical Trials A Mutation Based Approach John Christodoulou NSW Centre for Rett Syndrome Research Western Sydney Genetics.
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
Modeling Functional Genomics Datasets CVM Lessons 4&5 10 July 2007Bindu Nanduri.
From Chemoinformatics to Systems Chemical Biology Irene Kouskoumvekaki, Associate Professor, Computational Chemical Biology, CBS, DTU-Systems Biology #27803,
August 29, 2002InforMax Confidential1 Vector PathBlazer Product Overview.
Introduction to the biological pathway POSTECH NLP lab 발표자 : 정설경.
Integrative Approach to Abnormal Behavior Chapter 2.
Pathogenesis and pathology of parkinsonism Pathology.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Sleepwalking is a sleep disorder characterised by walking or other movements while still asleep. Also known as somnambulism. The individual appears awake,
Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
Emma Hahs, Brooke Armistead, Sarah Brown, Sok Kean Khoo Department of Cell and Molecular Biology, College of Liberal Arts and Sciences, Grand Valley State.
Biological pathway and systems analysis An introduction.
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
TRANSLATING GENOME WIDE ASSOCIATION STUDIES TO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS Alan E. Guttmacher, M.D. National Human Genome Research Institute.
Sample to Insight Alexander Kaplun, PhD Sep PGMD: a comprehensive pharmacogenomic database for personalized medicine and drug discovery.
Gene Discovery & Genome Browsing
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
A NEUROPEPTIDE THAT DRAMATICALLY ENHANCES LEARNING AND MEMORY POTENTIAL FOR COGNITIVE DRUG DEVELOPMENT John M. Stewart Department of Biochemistry University.
Alzheimer’s Disease and Myelin Degeneration RE|NOUS Jasmine Toor Week 6 Winter 2014 Meeting.
Parkinson’s Disease superKAT :).
From protein structure to function. The particular catalytic activity, binding properties or conformational changes of a protein. The complex, or.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.
Presented by Karen Xu. Introduction Cancer is commonly referred to as the “disease of the genes” Cancer may be favored by genetic predisposition, but.
약물유전체학 Pharmacogenomics Kangwon National Univ School of Medicine Hee Jae Lee PhD.
CS 374: Relating the Genetic Code to Gene Expression Sandeep Chinchali.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
Pharmacogenomics in Drug Development FDA Science Board April 9, 2003 Brian B. Spear, Ph.D. Director, Pharmacogenomics Abbott Laboratories.
09-Sep-2003 Predicting human risk with animal research: lessons learned from caffeine/ephedrine combinations Richard J. Briscoe, Ph.D. Safety Pharmacology.
Abstract Parkinson's disease (PD) is a well known disease estimated to affect 2% of people above age 60. It is a progressively debilitating disease affecting.
Zeevik Melamed & Dror Hollander Gil Ast Lab Sackler Medical School RNA Splicing & UCSC Genome Browser.
Introduction to biological molecular networks Colin Dewey BMI/CS 576 Fall 2015.
Chapter 1: Introduction to Anatomy and Physiology
Mapping Genetic Risk of Suicide Virginia Willour, Ph.D.
© 2017 SlidePlayer.com Inc. All rights reserved.